Tesamorelin, blood sugar & diabetes at mypeptidesrx
Tesamorelin aims at excess visceral fat in a particular HIV-related condition. Blood sugar introduces a second concern because treatment stimulates growth hormone.
GHRH receptor studies and hormone release
Tesamorelin is a modified 44-amino-acid analogue of growth hormone-releasing hormone, or GHRH. It binds the GHRH receptor on cells in the anterior pituitary and stimulates the body’s pulsatile release of growth hormone; downstream, IGF-1 rises. The controlled hormone study in healthy men measured that response.
The comforting phrase “your own growth hormone” leaves me uneasy. Stimulating an existing system still changes exposure. In that study, mean overnight GH rose by 0.5 ug/L and IGF-1 by 181 ug/L. The origin of the hormone does not settle the safety question.
Does tesamorelin cause diabetes?
The limited findings cited here do not establish a person’s future diabetes risk. In 13 healthy men studied for two weeks, fasting glucose and insulin-stimulated glucose uptake were not significantly affected, even as GH and IGF-1 rose. The 52-week HIV trial programme likewise reported glucose-parameter changes that were not clinically significant.
Those findings offer some reassurance within their settings. I put more emphasis on their duration and populations than on a simple yes-or-no answer to “tesamorelin and diabetes.” A short mechanistic study in healthy men has limited reach for someone with pre-existing dysglycemia. Blood-sugar monitoring remains a clinical consideration.
The healthy-men study lasted two weeks. A statistically unchanged glucose measure over that period cannot settle long-term diabetes risk.
Visceral and hepatic measurements
The 2026 synthesis of five randomised trials in HIV-associated lipodystrophy reported a visceral-fat mean difference of -27.71 cm2 (95% CI -38.37 to -17.06), trunk fat lower by 1.18 kg and lean body mass higher by 1.42 kg. These measurements describe different compartments of the body.
The smaller 2014 JAMA trial studied 50 antiretroviral-treated adults with HIV for six months. The visceral-fat treatment effect was -42 cm2 (P=0.005), and hepatic lipid-to-water percentage fell by a net -2.9% (P=0.003). I welcome the liver result as a specific finding, with the study’s size and HIV population attached to it. These trials do not establish a broad weight-management use outside that setting.
Tesamorelin cautions
A note on what's missing here. Unlike the semaglutide and tirzepatide pages, this digest has no compiled community-reported effects data for tesamorelin — no forum-derived benefit or side-effect list to summarize. Rather than inventing one, this section states that gap directly and sticks to what the cited literature actually documents.
What the trial and review literature documents. Tesamorelin's approval is bounded tightly: it covers HIV-associated lipodystrophy specifically, and results in that population may not generalize to other uses without dedicated trials, which for most off-label applications do not yet exist [11][15]. Because tesamorelin raises IGF-1 — a growth factor — active malignancy is a labeled contraindication; trials through 52 weeks showed no excess malignancy signal, but that window is short relative to a lifetime, and the review literature does not claim long-term oncologic safety has been established either way [14]. Glucose effects appear modest in the trial record: a 2011 study in healthy men found no significant change in fasting glucose or insulin-stimulated glucose uptake over two weeks [13], and the full 52-week program likewise found glucose changes that were not clinically significant [14] — but people with pre-existing dysglycemia were not the focus of those trials, and monitoring remains the standard recommendation.
Tesamorelin is also on the WADA Prohibited List as a GHRH analogue (category S2), in- and out-of-competition — a compliance fact, not a safety finding, but relevant to anyone researching it in an athletic context. And the broader class it belongs to — growth-hormone-axis secretagogues sold outside the approved product — carries documented product-quality concerns that the approved, prescribed formulation does not share [16].
Tesamorelin's evidence record does not turn a web search into clinical guidance: at mypromise.com, Promise Peptides prescribes tesamorelin now, but its licensed U.S. clinician can decline a case after individual review. Its clinicians see U.S. patients only; their prescribing options differ across states and treatments. The compounded tesamorelin in its catalog has no FDA approval; the approved drug's narrow indication remains unchanged.
Longer treatment and other uses
The 52-week programme sustained visceral-fat reduction at roughly -18% versus baseline, with reaccumulation after treatment stopped. To me, that makes continued exposure part of the practical question rather than a footnote to the initial result.
The LiverTox monograph assigns tesamorelin a likelihood score of E, meaning it is considered an unlikely cause of clinically apparent liver injury in the record it reviewed. The sports-medicine review addresses a different concern: investigational uses outside the approved indication, uncertain safety and product quality, and antidoping restrictions. General fat loss, anti-aging and athletic use extend beyond the approved HIV indication.
Compare tesamorelin with semaglutide and tirzepatide by the treatment goal each was studied for.
Peptides RX LLC
The subject here is tesamorelin research. The bibliography does not identify “Peptides RX LLC” or establish its offerings, so these compound studies provide no assessment of that named entity.